Male DCIS diagnosed after use of over-the-counter hormonal supplement.

Atypical ductal hyperplasia Ductal carcinoma in-situ Gynecomastia Male breast cancer Mastectomy

Journal

International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872

Informations de publication

Date de publication:
2019
Historique:
received: 16 10 2018
revised: 10 02 2019
accepted: 13 02 2019
pubmed: 25 3 2019
medline: 25 3 2019
entrez: 24 3 2019
Statut: ppublish

Résumé

Male breast cancer is a rare disease. Although epidemiologic and genetic factors are associated with male breast cancer, hormonal factors may also play a role. We report the case of a 39-year-old BRCA negative male patient taking a sexual performance enhancement supplement who presented with worsening asymmetric gynecomastia and unilateral spontaneous bloody nipple discharge and was found to have ductal carcinoma in-situ. The altered cellular environment related to the hormone contents of the supplement coincided with the rapid worsening of his gynecomastia and may have played a role in the development of the ductal carcinoma in-situ, or growth of an existing focus. The use of hormonal male enhancement supplements can lead to higher levels of androgens in users. It is possible for this altered hormonal environment to cause the growth of tumor or promote the progression of an existing focus.

Identifiants

pubmed: 30903856
pii: S2210-2612(19)30089-6
doi: 10.1016/j.ijscr.2019.02.028
pmc: PMC6430715
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

60-62

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Références

JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54
pubmed: 12381707
J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99
pubmed: 12953083
Ann Surg. 1992 May;215(5):451-7; discussion 457-9
pubmed: 1319699
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6
pubmed: 15668471
Lancet. 2006 Feb 18;367(9510):595-604
pubmed: 16488803
Ann Plast Surg. 2006 Mar;56(3):346
pubmed: 16508375
Breast Cancer Res Treat. 2007 May;103(1):11-21
pubmed: 17033919
Breast. 2007 Dec;16 Suppl 2:S147-54
pubmed: 18210656
Mayo Clin Proc. 2009 Nov;84(11):1010-5
pubmed: 19880691
Gynecol Endocrinol. 2012 Mar;28 Suppl 1:46-9
pubmed: 22394304
J Natl Cancer Inst. 2014 Mar;106(3):djt465
pubmed: 24552677
JAMA. 2015 Jan 13;313(2):165-73
pubmed: 25585328
Oncologist. 2015 Jun;20(6):586-92
pubmed: 25948676
JAMA Oncol. 2015 Oct;1(7):888-96
pubmed: 26291673
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279

Auteurs

S O Agbroko (SO)

Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn NY, United States. Electronic address: sagbroko@maimonidesmed.org.

K E Rojas (KE)

Department of Surgery, Maimonides Medical Center, Brooklyn NY, United States.

D M Manasseh (DM)

Department of Surgery, Maimonides Medical Center, Brooklyn NY, United States.

P Borgen (P)

Department of Surgery, Maimonides Medical Center, Brooklyn NY, United States.

Classifications MeSH